Regulatory approval
Published by the Health Canada. Approved
MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | BRAF p.V600E | Melanoma | Trametinib | |
| HC (1) | BRAF p.V600K | Melanoma | Trametinib | |
| HC (1) | BRAF p.V600E | High-Grade Glioma | Dabrafenib, Trametinib |
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-10-30 | Van Allen lab | Initial access of FDA approvals |